Gao Feng, Feng Xuefei, Li Xinyu
Clinical Laboratory of China-Japan Union Hospital, Jilin University, Changchun, China.
Front Pharmacol. 2025 Jan 24;16:1528752. doi: 10.3389/fphar.2025.1528752. eCollection 2025.
The liver performs crucial roles in energy metabolism, detoxification, and immune regulation. Hepatic diseases, including hepatitis, liver fibrosis, and liver cancer, have posed a significant threat to global health, emphasizing the critical need for the development of novel and effective treatment approaches. Nanotechnology, an emerging technology, has been extensively researched in medicine. Among the many types of nanomaterials, polymeric nanoparticles (NPs) are widely used in drug delivery systems. Compared to traditional therapies, they offer significant advantages in the treatment of liver disease by improving outcomes and reducing side effects. This review introduced the development of liver disease and discussed the application of natural polymers and synthetic polymers in their management. Furthermore, this paper reviewed the application of polymeric nanoparticles -mainly chitosan (CS), hyaluronic acid (HA), polyethylene glycol (PEG) and poly (lactic-co-glycolic acid) (PLGA)-in liver disease treatment, focusing on their use in various delivery systems for pure bioactive compounds of natural origin, drugs, nucleic acids, peptides, and others. Finally, the challenges and future perspectives of the NPs were discussed to provide guidance for further research directions, with the aim of promoting the clinical application of nanotherapeutics in treating hepatic diseases.
肝脏在能量代谢、解毒和免疫调节中发挥着关键作用。包括肝炎、肝纤维化和肝癌在内的肝脏疾病,已对全球健康构成重大威胁,这凸显了开发新颖且有效治疗方法的迫切需求。纳米技术作为一种新兴技术,已在医学领域得到广泛研究。在众多类型的纳米材料中,聚合物纳米颗粒(NPs)被广泛应用于药物递送系统。与传统疗法相比,它们在肝病治疗中具有显著优势,能够改善治疗效果并减少副作用。本综述介绍了肝脏疾病的发展情况,并讨论了天然聚合物和合成聚合物在其治疗中的应用。此外,本文综述了聚合物纳米颗粒——主要是壳聚糖(CS)、透明质酸(HA)、聚乙二醇(PEG)和聚乳酸-羟基乙酸共聚物(PLGA)——在肝病治疗中的应用,重点关注它们在各种递送系统中用于天然来源的纯生物活性化合物、药物、核酸、肽等的情况。最后,讨论了纳米颗粒面临的挑战和未来前景,为进一步的研究方向提供指导,旨在推动纳米治疗剂在肝病治疗中的临床应用。
Front Pharmacol. 2025-1-24
J Biomater Sci Polym Ed. 2023-6
Acta Pharm Sin B. 2021-8
Eur J Pharm Biopharm. 2013-11
Acta Pharm Sin B. 2019-1
Int J Mol Sci. 2022-11-20
Acta Biomater. 2014-2-8
Pharmaceuticals (Basel). 2025-3-16
Expert Opin Drug Deliv. 2024-6
Int J Biol Macromol. 2024-7
World J Gastroenterol. 2024-5-21
Colloids Surf B Biointerfaces. 2024-8